A Non-Pharmacological Paradigm Captures the Complexity in the Mechanism of Action of Poliprotect Against Gastroesophageal Reflux Disease and Dyspepsia

被引:0
|
作者
Caterbi, Sara [1 ]
Buttarini, Claudio [1 ]
Garetto, Stefano [1 ]
Moscardini, Isabelle Franco [1 ]
Ughetto, Stefano [1 ]
Guerrini, Angela [1 ]
Panizzi, Elena [1 ]
Rumio, Cristiano [2 ]
Mattioli, Laura [3 ]
Perfumi, Marina [3 ]
Maidecchi, Anna [4 ]
Cossu, Andrea [4 ]
Varannes, Stanislas Bruley des [5 ]
Regula, Jaroslaw [6 ,7 ]
Malfertheiner, Peter [8 ,9 ]
Sardi, Claudia [1 ]
Lucci, Jacopo [1 ]
机构
[1] Physiol Syst Hlth SpA, Bios Therapy, Local Aboca 20, I-52037 Sansepolcro, Italy
[2] Univ Milan, Dept Pharmacol & Biomol Sci, Via Trentacoste 2, I-20134 Milan, Italy
[3] Univ Camerino, Dept Expt Med & Publ Hlth, Via Madonna Carceri 9, I-62032 Camerino, Italy
[4] Soc Agr, Aboca SpA, Local Aboca 20, I-52037 Sansepolcro, Italy
[5] Univ Hosp, Inst Malad Appareil Digest, Dept Gastroenterol Hepatol & Clin Oncol, F-44000 Nantes, France
[6] Mar Sklodowska Curie Natl Res Inst Oncol, Dept Oncol Gastroenterol, PL-00001 Warsaw, Poland
[7] Ctr Postgrad Med Educ, Dept Gastroenterol Hepatol & Clin Oncol, PL-01813 Warsaw, Poland
[8] LMU Klinikum Med Klin & Poliklin II, Campus Grosshadern,Marchioninistr 15, D-81377 Munich, Germany
[9] Otto von Guericke Univ, Klin Gastroenterol Hepatol & Infektiol, D-39120 Magdeburg, Germany
关键词
Poliprotect; NeoBianacid; gastroesophageal reflux disease; dyspepsia; biophysical properties; non-pharmacological mechanism; emerging properties; medical device; novel R&D paradigm; MUCOSAL PROTECTION; EPITHELIAL BARRIER; ESOPHAGEAL MUCOSA; MODEL; PATHOGENESIS; OMEPRAZOLE; MANAGEMENT; HEARTBURN; INTEGRITY; ALGINATE;
D O I
10.3390/ijms26031181
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
When the protective mechanisms of the gastroesophageal mucosa are overwhelmed by injurious factors, the structural and functional mucosal integrity is compromised, resulting in a wide spectrum of disorders. Poliprotect has recently been shown to be non-inferior to standard-dose omeprazole for the treatment of endoscopy-negative patients with heartburn and/or epigastric pain or burning. Here, we provide preclinical data describing the mechanism of action of the Poliprotect formulation, a 100% natural, biodegradable, and environmental friendly medical device according to EU 2017/745 and containing UVCB (unknown or variable composition, complex-reaction products, or biological materials) substances of botanical and mineral origin, according to the REACH and European Chemical Agency definitions. Different in vitro assays demonstrated the capability of Poliprotect to adhere to mucus-secreting gastric cells and concomitantly deliver a local barrier with buffering and antioxidant activity. In studies conducted in accordance with systems biology principles, we evaluated the effects of this barrier on human gastric cells exposed to acidic stress. Biological functions identified via Ingenuity Pathway Analysis highlighted the product's ability to create a microenvironment that supports the mucosal structural and functional integrity, promotes healing, and restores a balanced mucosal inflammatory status. Additionally, transepithelial electrical resistance and an Ussing chamber showed the product's capability of preserving the integrity of the gastric and esophageal epithelial barriers when exposed to an acid solution. Two in vivo models of erosive gastropathy further highlighted its topical protection against ethanol- and drug-induced mucosal injury. Overall, our findings sustain the feasibility of a paradigm shift in therapeutics R&D by depicting a very innovative and desirable mode of interaction with the human body based on the emerging biophysical, rather than the pharmacological properties of these therapeutic agents.
引用
收藏
页数:29
相关论文
共 24 条
  • [21] Characteristics of Response to Intragastric Pressure (IGP) Measurement Following Air Insufflation in Patients with Functional Dyspepsia (FD) and Patients with Non-Erosive Gastroesophageal Reflux Disease (NERD)
    Suzuki, Tsuyoshi
    Kira, Fumitaka
    Nishimura, Shuji
    Suyama, Yuki
    GASTROENTEROLOGY, 2009, 136 (05) : A183 - A183
  • [22] The Therapeutic and Diagnostic Value of 2-week High Dose Proton Pump Inhibitor Treatment in Overlapping Non-erosive Gastroesophageal Reflux Disease and Functional Dyspepsia Patients
    Kriengkirakul, Chatchai
    Patcharatrakul, Tanisa
    Gonlachanvit, Sutep
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 18 (02) : 174 - 180
  • [23] Comparing Gastroesophageal Reflux Disease (GERD) and Non-GERD Patients Based on Knowledge Level of Acute Myocardial Infarction Symptoms, Risk Factors and Immediate Action Taken in Eastern Province, Saudi Arabia
    Bohamad, Abdullah H.
    Buali, Hadeel H.
    Aljasem, Jinan M.
    Alhussain, Ali H.
    Alamer, Mohammed A.
    Elsheikh, Eman
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (02)
  • [24] Mechanism of action of Orthosiphon stamineus against non-alcoholic fatty liver disease: Insights from systems pharmacology and molecular docking approaches
    Alshehade, Salah Abdulrazak
    Zarzour, Raghdaa Hamdan Al
    Murugaiyah, Vikneswaran
    Lim, Sharoen Yu Ming
    El-Refae, Huda Ghaleb
    Alshawsh, Mohammed Abdullah
    SAUDI PHARMACEUTICAL JOURNAL, 2022, 30 (11) : 1572 - 1588